Adicet Bio
Off-the-shelf allogeneic gamma delta T cell therapies
- Sector
- Biotech
- Headquarters
- MENLO PARK, CA
- Founded
- 2014
- Latest Form D
- $80M, Oct 2019
- Total capital
- $106M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $106M
- 3 Form D · last Oct 2019
- 85 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 11 pending · first 2021
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$80M
- Private capital raisedForm D · SEC · 2nd filing$11.3M
- Private capital raisedForm D · SEC · 1st filing$14.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Aya JakobovitsResearcherDirectorLinked by 3 patents
- Anne AltmeyerExecutive OfficerNamed in SEC Form D filings
- Asish XavierDirectorNamed in SEC Form D filings
- Brian HoganExecutive OfficerNamed in SEC Form D filings
- Carl GordonDirectorNamed in SEC Form D filings
- Carrie KrehlikExecutive OfficerNamed in SEC Form D filings
Show all 16 people
- Donald SantelExecutive Officer, DirectorNamed in SEC Form D filings
- Erez ChimovitsDirectorNamed in SEC Form D filings
- Florent GrosDirectorNamed in SEC Form D filings
- Francesco GaliniExecutive OfficerNamed in SEC Form D filings
- Jonathan SilversteinDirectorNamed in SEC Form D filings
- Michal SilverbergDirectorNamed in SEC Form D filings
- Nathan HubbardExecutive OfficerNamed in SEC Form D filings
- Steward AbbotExecutive OfficerNamed in SEC Form D filings
- Stewart AbbotExecutive OfficerNamed in SEC Form D filings
- Yair SchindelDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 15- GrantedAntibodies Capable Of Binding HLA-A2/TYRD In An Hla Restricted Manner And Uses ThereofUSPTOUS 11,485,785
- GrantedMethods For Selective Expansion Of Gamma Delta T-cell Populations And Compositions ThereofUSPTOUS 11,299,708
- GrantedEngineered Gamma Delta T-cellsUSPTOUS 11,135,245
Show all 15 patent records
- Antibodies Capable Of Binding HLA-A2/TYRD In An Hla Restricted Manner And Uses ThereofNov 1, 2022 · US 11,485,785Granted
- Methods For Selective Expansion Of Gamma Delta T-cell Populations And Compositions ThereofApr 12, 2022 · US 11,299,708Granted
- Engineered Gamma Delta T-cellsOct 5, 2021 · US 11,135,245Granted
- Affinity Entities Comprising A Tcr-like Antibody Binding Domain With High Affinity And Fine Specificity And Uses Of SameMay 11, 2021 · US 11,001,642Granted
- T Cell Receptor Like Antibodies Having Fine SpecificityJun 28, 2018 · Application 15579974Pending
- Methods For Selective In Vivo Expansion Of Gamma Delta T-cell Populations And Compositions ThereofApplication 62774817Pending
- Methods For Selective Expansion Of DELTA-3 Gamma Delta T-cell Populations And Compositions ThereofApplication PCTUS2018061384Pending
- Methods For Expanding Gamma Delta T-cell Populations With Multivalent Agents And Compositions ThereofApplication PCTUS2020063177Pending
- COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED yo-T CELLS FOR TREATMENT OF SOLID TUMORSApplication PCTUS2019054144Pending
- Methods For Selective Expansion Of DELTA-3 Gamma Delta T-cell Populations And Compositions ThereofApplication 62586782Pending
- COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED yo-T CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORSApplication PCTUS2019054132Pending
- Methods For Selective Expansion Of Gamma Delta T-cell Populations And Compositions ThereofApplication PCTUS2017032530Pending
- Methods For Selective Expansion Of Gamma Delta T-cell Poplulations And Compositions ThereofApplication 62335572Pending
- Engineered Gamma Delta T-cellsApplication PCTUS2015061189Pending
- Methods For Selective In Vivo Expansion Of Gamma Delta T-cell Populations And Compositions ThereofApplication PCTUS2019064319Pending
Related companies, and why
- JME Group Associates IncSimilar federal contract value in Biotech · null in contracts
- OTHRAM, INC.Similar federal contract value in Biotech · null in contracts
- Synnovation TherapeuticsSimilar federal contract value in Biotech · null in contracts
- REGENXBIO Inc.Similar federal contract value in Biotech · null in contracts
- RallybioSimilar federal contract value in Biotech · null in contracts
- Autobahn TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .